1. Home
  2. BLNK vs RIGL Comparison

BLNK vs RIGL Comparison

Compare BLNK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLNK
  • RIGL
  • Stock Information
  • Founded
  • BLNK 2009
  • RIGL 1996
  • Country
  • BLNK United States
  • RIGL United States
  • Employees
  • BLNK N/A
  • RIGL N/A
  • Industry
  • BLNK Industrial Specialties
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLNK Consumer Discretionary
  • RIGL Health Care
  • Exchange
  • BLNK Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • BLNK 163.4M
  • RIGL 486.4M
  • IPO Year
  • BLNK N/A
  • RIGL 2000
  • Fundamental
  • Price
  • BLNK $1.50
  • RIGL $17.32
  • Analyst Decision
  • BLNK Buy
  • RIGL Buy
  • Analyst Count
  • BLNK 7
  • RIGL 5
  • Target Price
  • BLNK $5.64
  • RIGL $34.80
  • AVG Volume (30 Days)
  • BLNK 4.9M
  • RIGL 316.4K
  • Earning Date
  • BLNK 11-07-2024
  • RIGL 11-07-2024
  • Dividend Yield
  • BLNK N/A
  • RIGL N/A
  • EPS Growth
  • BLNK N/A
  • RIGL N/A
  • EPS
  • BLNK N/A
  • RIGL 0.22
  • Revenue
  • BLNK $138,728,000.00
  • RIGL $157,374,000.00
  • Revenue This Year
  • BLNK N/A
  • RIGL $48.98
  • Revenue Next Year
  • BLNK $22.16
  • RIGL $14.43
  • P/E Ratio
  • BLNK N/A
  • RIGL $78.31
  • Revenue Growth
  • BLNK 15.13
  • RIGL 21.65
  • 52 Week Low
  • BLNK $1.38
  • RIGL $7.48
  • 52 Week High
  • BLNK $3.75
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • BLNK 45.10
  • RIGL 38.25
  • Support Level
  • BLNK $1.38
  • RIGL $15.61
  • Resistance Level
  • BLNK $1.62
  • RIGL $17.36
  • Average True Range (ATR)
  • BLNK 0.10
  • RIGL 1.31
  • MACD
  • BLNK -0.00
  • RIGL -0.25
  • Stochastic Oscillator
  • BLNK 40.00
  • RIGL 50.75

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: